Blemaren - instructions for use, doses, side effects, contraindications

Similar drugsTo uncover

Dosage form: & nbsp

tablets, effervescent

Composition:

1 tablet contains:

Citric acid 1197.0 mg

Potassium hydrogen carbonate - 967.5 mg

Sodium citrate - 835.5 mg

Excipients:

Lactose monohydrate (115.0 mg), mannitol (105.0 mg), adipic acid (35.0 mg), macrogol 6000 (100.0 mg), sodium saccharinate (10.0 mg), lemon flavor (35.0 mg).

Description:

White, round, flat, faceted pills with the smell of lemon.

Pharmacotherapeutic group:Treatment for nephrolithiasis

ATX: & nbsp

Drugs for the treatment of nephrourolythiasis

Pharmacodynamics:

Dissolves and prevents the formation of uric acid stones by alkalinizing urine to pH 6.6 - 6.8 (with a pH of 6.6-6.8, urinary salts dissolve greatly). In addition, it reduces the excretion of calcium, improves the solubility of calcium oxalate in urine, inhibits the formation of crystals and, consequently, prevents the formation of calcium oxalate stones.

Pharmacokinetics:

Bioavailability is about 100%. It is excreted by the kidneys.

Indications:

- dissolution of uric acid and calcium oxalate stones and prevention of their formation;

- dissolution of mixed uric acid-oxalate stones (with an oxalate content of less than 25%);

- alkalinization of urine in people receiving cytotoxic drugs or drugs that increase the excretion of uric acid;

- symptomatic treatment of porphyria of the skin.

Contraindications:

hypersensitivity;

acute and chronic renal failure;

metabolic alkalosis;

- urinary tract infections caused by microorganisms that break down urea;

urine pH is above 7;

- the need to comply with a strict salt-free diet (for example, with severe forms of hypertension);

- Children under 12 years of age (since there is insufficient clinical experience with this age group).

Pregnancy and lactation:

There is no confirmed data on the undesirable effects of Blimaren® drug during pregnancy and during breastfeeding. Taking the drug is possible after consulting a doctor.

Dosing and Administration:Before ingestion, tablets are dissolved in 200 ml of liquid (tea, fruit juices, or alkaline mineral water). The daily dose is 2-6 tablets.
The daily dose is evenly distributed throughout the day and is taken after a meal.
The dose is considered correctly selected if the pH during the day is within the range of 6.2 - 7.0 (for dissolution of uric acid stones); 7.5 - 8.5 (for cystine stones);
7.2 - 7.5 (for the treatment of porphyria); at least 7.0 (in the treatment of cytostatics). If the pH value of urine is lower than indicated, the dose should be increased, if higher - reduced. Duration of treatment is 4-6 months.
Efficiency monitoring (urine pH determination) is carried out 3 times a day, before each single dose is taken using indicator paper. The resulting color on paper is compared for 2 minutes with a scale and enter the value in the control calendar.
In the presence of cystine stones and the treatment of porphyria, a special indicator paper with a pH of 7.2 to 9.7 should be used to monitor the efficacy.

Side effects:

Allergic reactions, swelling (sodium retention), metabolic alkalosis, dyspepsia.

Interaction:

Simultaneous administration of preparations containing citrates and aluminum can lead to increased absorption of aluminum. The interval between doses of such drugs should be at least 2 hours. The effect of cardiac glycosides may be weakened, with their combined appointment with the Blemaren® preparation, due to the presence of potassium in the formulation. Some drugs that lower blood pressure (antagonists of aldysyuteron,potassium-sparing diuretics, angiotensin-converting enzyme blockers), as well as anti-inflammatory non-steroid agents and analgesics can reduce the excretion of potassium. The possibility of simultaneous reception of such funds is established by the doctor.

Special instructions:

The average daily dose (4 effervescent tablets) contains about 1.5 mg of potassium and 0.9 g of sodium (should be taken into account in patients with reduced intake of table salt). Can be used for chronic kidney failure, not accompanied by a delay of potassium ions. Can be prescribed to patients with diabetes mellitus. When dissolving uric acid stones, the daily dose should not be exceeded, because with increasing pH above 7.0, phosphate precipitation occurs on uric acid crystals, which prevents their further dissolution. During treatment, the intake of foods rich in proteins and purine bases should be restricted, and sufficient fluid intake (at least 1.5-2 liters) should be ensured.

Effect on the ability to drive transp. cf. and fur:

The drug does not affect the ability to drive vehicles and mechanisms that require increased attention.

Form release / dosage:

The tablets are effervescent.

Packaging:

For 20 tablets in a plastic tube, ukuporennuyu plastic cover with a desiccant. 4 tubes together with indicator paper, a control calendar and instructions for use are placed in a cardboard box.

Storage conditions:

List B. Store at a temperature of no higher than 25 ° C.

Keep out of the reach of children!

After opening, protect from moisture!

Shelf life:

4 years.

Do not use after the expiration date.

Terms of leave from pharmacies:Without recipe

Registration number:LSR-001331/07

Date of registration:28.06.2007

Expiration Date:Unlimited

The owner of the registration certificate:Esparma GmbHEsparma GmbH Germany

Manufacturer: & nbsp

ALLPHAMED PHARBIL ARZNEIMITTEL, GmbH Germany

Representation: & nbspESPARMA GmbH ESPARMA GmbH Germany

Information update date: & nbsp18.02.2017

Illustrated instructions

Instructions

Blamaren® (Blemaren®)